These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2300193)

  • 1. Swiss company takes a 60 per cent stake in Genentech.
    Gershon D
    Nature; 1990 Feb; 343(6258):495. PubMed ID: 2300193
    [No Abstract]   [Full Text] [Related]  

  • 2. Merck wipes Serono off Swiss biotech map.
    Urquhart L
    Nat Biotechnol; 2006 Nov; 24(11):1303. PubMed ID: 17093457
    [No Abstract]   [Full Text] [Related]  

  • 3. Genentech shares. Allegation of insider dealing.
    Gershon D
    Nature; 1990 May; 345(6271):102. PubMed ID: 2336100
    [No Abstract]   [Full Text] [Related]  

  • 4. Biotechnology. Mixed reactions to merger.
    Gershon D
    Nature; 1990 Feb; 343(6260):681. PubMed ID: 2304541
    [No Abstract]   [Full Text] [Related]  

  • 5. Biotechnology company's shares dive 67% after drug failure.
    Dobson R
    BMJ; 2000 Oct; 321(7268):1039. PubMed ID: 11053161
    [No Abstract]   [Full Text] [Related]  

  • 6. In-licensing as a business model.
    Schafer DP
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE36-9. PubMed ID: 12089585
    [No Abstract]   [Full Text] [Related]  

  • 7. How Genentech got it.
    Stipp D
    Fortune; 2003 Jun; 147(11):81-2, 84, 86 passim. PubMed ID: 12800575
    [No Abstract]   [Full Text] [Related]  

  • 8. Millennium mergers bring pipeline.
    Dove A
    Nat Biotechnol; 1999 Dec; 17(12):1151. PubMed ID: 10585700
    [No Abstract]   [Full Text] [Related]  

  • 9. Genzyme and Isis strike megadeal.
    Mack GS
    Nat Biotechnol; 2008 Mar; 26(3):251-3. PubMed ID: 18327216
    [No Abstract]   [Full Text] [Related]  

  • 10. Best-selling human medicines 2002-2004.
    Maggon K
    Drug Discov Today; 2005 Jun; 10(11):739-42. PubMed ID: 15922927
    [No Abstract]   [Full Text] [Related]  

  • 11. Signs of life in Q2.
    Yang W
    Nat Biotechnol; 2009 Aug; 27(8):686. PubMed ID: 19668166
    [No Abstract]   [Full Text] [Related]  

  • 12. Genentech grapples with direct offer.
    Huggett B
    Nat Biotechnol; 2009 Mar; 27(3):212. PubMed ID: 19270652
    [No Abstract]   [Full Text] [Related]  

  • 13. Big pharma swallows biotech's pride.
    Huggett B
    Nat Biotechnol; 2008 Sep; 26(9):955-6. PubMed ID: 18779785
    [No Abstract]   [Full Text] [Related]  

  • 14. Genentech faces the consequences of growth.
    Ransom J
    Nat Biotechnol; 2007 Apr; 25(4):371. PubMed ID: 17420731
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmas partner in venture seeking drug discovery tools.
    Mack GS
    Nat Biotechnol; 2008 Sep; 26(9):960-1. PubMed ID: 18779790
    [No Abstract]   [Full Text] [Related]  

  • 16. Bring the magic back to the bullets.
    Nat Biotechnol; 2006 Dec; 24(12):1489. PubMed ID: 17160046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new prescription for your portfolio.
    Clifford L; O'Keefe B; Stires D
    Fortune; 2001 Jul; 144(2):74-6, 78, 80. PubMed ID: 11471357
    [No Abstract]   [Full Text] [Related]  

  • 18. How do you measure "success" in a biotechnology company?
    Greetham EM
    Nat Biotechnol; 1998 May; 16 Suppl():59-60. PubMed ID: 9591275
    [No Abstract]   [Full Text] [Related]  

  • 19. Value drivers in licensing deals.
    Arnold K; Coia A; Saywell S; Smith T; Minick S; Löffler A
    Nat Biotechnol; 2002 Nov; 20(11):1085-9. PubMed ID: 12410249
    [No Abstract]   [Full Text] [Related]  

  • 20. King of the pill. Pfizer is the biggest drug company ever. Can it become the best?
    Simons J
    Fortune; 2003 Apr; 147(7):94-6, 100, 102. PubMed ID: 12698860
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.